EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. - Wikidata - wikimedia - TriplyDB

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

http://www.wikidata.org/entity/Q34642314

about

Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction Invasive urodynamic studies for the management of LUTS in men with voiding dysfunction Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia New therapeutic strategies for the treatment of male lower urinary tract symptoms Nocturia: The circadian voiding disorder Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery Overactive bladder Korean clinical practice guideline for benign prostatic hyperplasia Medical management of neurogenic bladder with oral therapy Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia The TURis System for Transurethral Resection of the Prostate: A NICE Medical Technology Guidance Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review Current use of phosphodiesterase inhibitors in urology Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia Holmium laser enucleation of the prostate: patient selection and perspectives Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis Custom 4-Plex DiLeu Isobaric Labels Enable Relative Quantification of Urinary Proteins in Men with Lower Urinary Tract Symptoms (LUTS)P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms.Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies.Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial.One day surgery in the treatment of benign prostatic enlargement with thulium laser: A single institution experience.Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies.Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia – integrated data from 1,499 study participants.A national benchmark for the initial assessment of men with LUTS: data from the 2010 Royal College of Physicians National Audit of Continence Care.Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women.Correlation between urothelial differentiation and sensory proteins P2X3, P2X5, TRPV1, and TRPV4 in normal urothelium and papillary carcinoma of human bladder.Measuring change in prostate size after holmium laser enucleation: A prospective study.Lower urinary tract symptoms: thinking beyond the urinary tract.Initial treatment of men with newly diagnosed lower urinary tract dysfunction in the Veterans Health Administration The influence of depression, anxiety and somatization on the clinical symptoms and treatment response in patients with symptoms of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

P2860

Q21256691-6D6CBB49-80A5-4436-A25B-0C228D08334F Q24186369-1B75EAC6-DCDC-467D-A668-3B93EB60D636 Q24194219-D3252ACF-7790-4F82-ACD3-EE15F4967DD5 Q26741226-85A97789-B4D5-4856-8EDD-DD7D06C5F27D Q26746138-1EE2DED9-7A65-411A-94A3-6CB4EB67A758 Q26747755-6D9207F3-AB10-430B-9631-F60D54CB1A10 Q26749608-756A9B23-8EB2-4B1C-972A-7ED7F3116AB0 Q26766174-FEBD9E8A-C7F2-40AF-B7CA-1B5E53CEFD24 Q26766302-B846AE22-4E32-4DC3-832F-B3F4D03F673D Q26767313-2498BE71-F72E-44C3-8745-BC8779BD4F8C Q26770415-AA3123E6-C9ED-4744-8FED-33FFB1C3609C Q26770425-169085DA-14E0-449C-BBCC-A7CCF3C1EC5C Q26773353-02D07943-ED64-49E4-B25B-35DC36084C43 Q26775925-05B51E4C-2297-423A-9A6F-6A301E11581F Q26783529-5E6A5FC5-ED44-436A-BF5E-6FB49CEE2F44 Q26785752-AC8CA616-0701-4792-BEA4-258C9238D5C9 Q26795512-E729F292-1535-44DA-9BA5-45EB7FD24A5D Q26796381-DCDE5B4E-34A5-42C0-AB52-4FE7520CE5C5 Q26825032-1B9E1647-CFB7-4996-BD60-69ED973FDDE8 Q26991636-281EEE79-D740-4D16-A3B8-05666BB570AD Q27008847-82BF16FC-073E-451C-B6AD-94931DD63318 Q27028037-8D73F3C9-C2BF-44EE-B8BC-6B2BFCFA047C Q28072328-8B8918B4-DF30-413E-86E3-24F8E4C1D0AC Q28542960-A503D653-B671-4C78-BD6B-EB932D7B8F5D Q28547212-341A7180-B4D7-4F4A-B59A-5B6E34AF7C06 Q28551296-DDB228DF-DB8F-4775-8758-00F2B8195DFA Q30249162-DECE3DE5-FC04-440F-9318-D7DEC2389E72 Q30373008-A5F58AC3-E5DA-45C8-8220-8C028D8E3A9D Q30488666-B3BAC6B3-5B55-46C8-BE9C-82959E771779 Q30649873-BAC6459B-4219-4CE4-A06A-9DE91EF7E58F Q30751186-D29BBC3C-9D11-4C95-A2D4-4B93AF0384B1 Q30848036-43606C31-7EC9-4BCF-9AB4-37C32FB4E8FA Q31004954-B756C2ED-DA3D-4A64-AA8B-28165AFFD9D6 Q31110115-F5AEB467-825D-43B9-BFC4-69B49A00711F Q33601008-7B6BF8A8-1F74-4489-BDD9-FCCF13BCD89C Q33608790-11A3FE8E-25C5-43FB-895D-47DA0F2B5A57 Q33641970-86BCA9AB-FA74-4D23-A058-52055388AE99 Q33956004-47ACD209-049C-4E77-8A0B-23C6C2A6D5F9 Q33959807-0C35E49A-FDC0-40AC-A1F1-EA3A637F184E Q34030026-56F1120B-BBE2-4E9B-995A-35CFD1D28234

P2860

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

http://www.wikidata.org/entity/Q34642314

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@ast

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@en

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@nl

type

label

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@ast

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@en

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@nl

prefLabel

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@ast

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@en

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@nl

P1433

Q34642314-C80F7A8A-676F-4B4E-B5E4-92D40751937D

P1476

Q34642314-5CEEEEF0-CCE6-4806-A3AA-4FBF0C81C364

P2093

Q34642314-03199D78-95DC-496F-BF30-0D1302CEFE8D

Q34642314-317A1B92-C218-4647-87D0-E28671A03020

Q34642314-38D77C70-BBFD-42C6-9D78-7A46F5DCB623

Q34642314-A95B2B51-A975-44FE-92BE-9159B8B4469E

Q34642314-D54B0A9E-4F30-4499-A4F4-1CA1FCD6A432

Q34642314-D8DB4A6E-84C8-4A38-A201-EA7DBBC5E002

Q34642314-DDD9639C-3B6E-4BEE-8B5B-A0BD205C5A58

P304

Q34642314-81F211FD-F8A6-466E-BC8E-E8093D8D6BDC

P31

Q34642314-7388516C-1578-43D0-B47C-1A2B3EDA4217

P356

Q34642314-7C1BDEF6-89EF-44E9-85E7-EDC58A481C5B

P407

Q34642314-C2C18395-6AB9-41C4-98B5-E72F4C458118

P433

Q34642314-EBCBAB6A-E202-4144-B905-53D844278592

P478

Q34642314-EA856A51-E1A8-46BA-BD26-62493F9C2E43

P50

Q34642314-089AE2D6-D658-4430-A17C-201ABD23DB8F

Q34642314-6DB78DDF-A624-4B4A-BC77-8E8979B03116

Q34642314-C74BDCF1-1A14-4985-B410-E4077A68F345

P577

Q34642314-12E5887B-F033-464E-A53D-E53093C76F04

P698

Q34642314-F529D356-FD7D-4079-B046-6D4293A95152

P356

J.EURURO.2013.03.004

P1433

European Urology

P1476

EAU guidelines on the treatmen ...... benign prostatic obstruction.

@en

P2093

Alexander Bachmann

http://www.w3.org/2001/XMLSchema#string

European Association of Urology

http://www.w3.org/2001/XMLSchema#string

James N'dow

http://www.w3.org/2001/XMLSchema#string

Jean J de la Rosette

http://www.w3.org/2001/XMLSchema#string

Jørgen Nordling

http://www.w3.org/2001/XMLSchema#string

Matthias Oelke

http://www.w3.org/2001/XMLSchema#string

Stavros Gravas

http://www.w3.org/2001/XMLSchema#string

P304

118-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2013.03.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Aurélien Descazeaud

Martin C. Michel

P577

2013-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23541338

http://www.w3.org/2001/XMLSchema#string